Fosca Niero

605 total citations
13 papers, 218 citations indexed

About

Fosca Niero is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Fosca Niero has authored 13 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Virology and 5 papers in Hepatology. Recurrent topics in Fosca Niero's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (7 papers) and HIV/AIDS Research and Interventions (6 papers). Fosca Niero is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (7 papers) and HIV/AIDS Research and Interventions (6 papers). Fosca Niero collaborates with scholars based in Italy, United States and South Africa. Fosca Niero's co-authors include Giuliano Rizzardini, Elena Ricci, Simona Landonio, Paolo Bonfanti, Monica Schiavini, Gaetana Sterrantino, Maria Vittoria Cossu, Giovanni Cenderello, Anna Maria Cattelan and Giuseppe Vittorio De Socio and has published in prestigious journals such as Journal of Hepatology, The American Journal of Gastroenterology and AIDS.

In The Last Decade

Fosca Niero

13 papers receiving 216 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fosca Niero Italy	9	121	85	85	69	62	13	218
José Antonio Mata‐Marín Mexico	9	121 1.0×	78 0.9×	150 1.8×	101 1.5×	61 1.0×	41	273
Laura Albini Italy	11	170 1.4×	113 1.3×	111 1.3×	55 0.8×	127 2.0×	16	344
Alessandra Calabresi Italy	10	150 1.2×	94 1.1×	78 0.9×	21 0.3×	93 1.5×	15	297
Giuseppe Bruno Italy	10	102 0.8×	93 1.1×	96 1.1×	47 0.7×	47 0.8×	26	253
Berta Pernas Spain	10	116 1.0×	90 1.1×	77 0.9×	55 0.8×	32 0.5×	23	241
Paola Zuccalà Italy	8	77 0.6×	36 0.4×	125 1.5×	130 1.9×	26 0.4×	13	278
Paolo Tundo Italy	7	127 1.0×	83 1.0×	84 1.0×	58 0.8×	31 0.5×	10	201
V. Jubault France	7	102 0.8×	83 1.0×	65 0.8×	12 0.2×	74 1.2×	9	222
Yann Quertainmont France	7	85 0.7×	35 0.4×	114 1.3×	64 0.9×	37 0.6×	14	200
María Trujillo‐Rodríguez Spain	8	93 0.8×	77 0.9×	37 0.4×	38 0.6×	42 0.7×	19	152

Countries citing papers authored by Fosca Niero

Since Specialization

Citations

This map shows the geographic impact of Fosca Niero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fosca Niero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fosca Niero more than expected).

Fields of papers citing papers by Fosca Niero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fosca Niero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fosca Niero. The network helps show where Fosca Niero may publish in the future.

Co-authorship network of co-authors of Fosca Niero

This figure shows the co-authorship network connecting the top 25 collaborators of Fosca Niero. A scholar is included among the top collaborators of Fosca Niero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fosca Niero. Fosca Niero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Capetti, Amedeo, Giuseppe Vittorio De Socio, Maria Vittoria Cossu, et al.. (2018). Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clinical Trials. 19(6). 242–248. 12 indexed citations

Passerini, Matteo, Monica Schiavini, C. Magni, et al.. (2018). Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience. European Journal of Gastroenterology & Hepatology. 30(10). 1208–1215. 19 indexed citations

Capetti, Amedeo, Maria Vittoria Cossu, Giancarlo Orofino, et al.. (2017). A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data. BMC Infectious Diseases. 17(1). 658–658. 36 indexed citations

Capetti, Amedeo, Laura Carenzi, Fosca Niero, et al.. (2017). Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs. Medicine. 96(7). e5728–e5728. 3 indexed citations

Milazzo, Laura, C. Magni, Fosca Niero, et al.. (2017). Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience. European Journal of Gastroenterology & Hepatology. 29(11). 1231–1234. 1 indexed citations

Capetti, Amedeo, et al.. (2017). Durability of Boosted Atazanavir (ATV) or Darunavir (DRV) Plus Maraviroc (MVC) Dual rescue Therapy in Poorly Adherent Subjects in View of Long-Acting Drugs. Journal of Antivirals & Antiretrovirals. 9(4). 1 indexed citations

Capetti, Amedeo, Gaetana Sterrantino, Maria Vittoria Cossu, et al.. (2016). Salvage Therapy or Simplification of Salvage Regimens with Dolutegravir plus Ritonavir-Boosted Darunavir Dual Therapy in Highly cART-Experienced Subjects: An Italian Cohort. Antiviral Therapy. 22(3). 257–262. 14 indexed citations

Cento, Valeria, Simona Landonio, Francesca De Luca, et al.. (2013). A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy. Antiviral Therapy. 18(4). 1–5. 14 indexed citations

Piconi, Stefania, S. Parisotto, Giuliano Rizzardini, et al.. (2012). Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS. 27(3). 381–389. 44 indexed citations

10.

Svicher, Valentina, Caterina Gori, Valeria Micheli, et al.. (2008). The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. Journal of Hepatology. 50(3). 461–470. 31 indexed citations

11.

Milazzo, Laura, Mara Biasin, Luca Piacentini, et al.. (2006). Thalidomide in the Treatment of Chronic Hepatitis C Unresponsive to Alfa-Interferon and Ribavirin. The American Journal of Gastroenterology. 101(2). 399–402. 11 indexed citations

12.

Quirino, Tiziana, Fosca Niero, Elena Ricci, et al.. (2000). Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected Patients. Antiviral Therapy. 5(3). 195–197. 25 indexed citations

13.

Galli, Massimo, Massimo Musicco, Cristina Gervasoni, et al.. (1996). No Evidence of a Higher Risk of Progression to AIDS in Patients with HIV-1-Related Severe Thrombocytopenia. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 12(3). 268–275. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact